Floatz logo

ide034

Endometrium Cancer

IDEAYA BiosciencesPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

44 Active assets in the Endometrium Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BBB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
Eli Lilly and Company
Phase 3BB
Carboplatin
Eli Lilly and Company
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

ide034 is also rated in:

ovarian serous adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
esophageal squamous cell carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →